Steven Gore

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. pmc A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
    Haematologica 98:1067-72. 2013
  2. ncbi request reprint Inhibitors of signaling in myelodysplastic syndrome
    Steven D Gore
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 288, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Best Pract Res Clin Haematol 17:613-22. 2004
  3. ncbi request reprint In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Res 33:S2-6. 2009
  4. ncbi request reprint Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Control 16:2-10. 2009
  5. pmc Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CRB1 288, 1650 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 28:1047-53. 2010
  6. pmc Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Cancer Control 15:40-9. 2008
  7. ncbi request reprint Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
  8. doi request reprint Epigenetic targets in human neoplasms
    Tamer E Fandy
    Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Epigenomics 2:221-32. 2010
  9. pmc New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Hematology Am Soc Hematol Educ Program 2011:550-5. 2011
  10. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005

Detail Information

Publications48

  1. pmc A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD, USA
    Haematologica 98:1067-72. 2013
    ....
  2. ncbi request reprint Inhibitors of signaling in myelodysplastic syndrome
    Steven D Gore
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Cancer Research Building 288, 1650 Orleans Street, Baltimore, MD 21231 1000, USA
    Best Pract Res Clin Haematol 17:613-22. 2004
    ..Future therapies in MDS will attempt to resolve cytopenias, eliminate malignant clones and allow differentiation by attacking specific mechanisms of the disease...
  3. ncbi request reprint In vitro basis for treatment with hypomethylating agents and histone deacetylase inhibitors: can epigenetic changes be used to monitor treatment?
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD 21287, USA
    Leuk Res 33:S2-6. 2009
    ..Trials are ongoing to investigate early methylation changes and DNA damage markers to understand the mechanisms of these drugs and as potential predictors of clinical response...
  4. ncbi request reprint Enhancing survival outcomes in the management of patients with higher-risk myelodysplastic syndromes
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Cancer Control 16:2-10. 2009
    ..This review examines the classification and diagnosis of higher-risk MDS patients, the management goals for these patients, clinical experience involved with treatments, guidelines, and recommendations for therapeutic options...
  5. pmc Single cycle of arsenic trioxide-based consolidation chemotherapy spares anthracycline exposure in the primary management of acute promyelocytic leukemia
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, CRB1 288, 1650 Orleans St, Baltimore, MD 21231, USA
    J Clin Oncol 28:1047-53. 2010
    ..Future studies should continue to focus on reducing the toxicity of treatment without increasing the relapse rate...
  6. pmc Future directions in myelodysplastic syndrome: newer agents and the role of combination approaches
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Cancer Control 15:40-9. 2008
    ..Utilizing convergent or complementary molecular mechanisms with in vitro or in vivo evidence of synergy is a fresher and maybe a more efficacious approach to combination therapy...
  7. ncbi request reprint Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms
    Steven D Gore
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21287, USA
    Cancer Res 66:6361-9. 2006
    ..The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials...
  8. doi request reprint Epigenetic targets in human neoplasms
    Tamer E Fandy
    Division of Hematologic Malignancies, The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, 1650 Orleans Street, Baltimore, MD 21231, USA
    Epigenomics 2:221-32. 2010
    ..Evaluating the combination of different epigenetic modifiers and ensuring their optimization are the next challenges towards the establishment of epigenetic therapy...
  9. pmc New ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndrome
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD 21231, USA
    Hematology Am Soc Hematol Educ Program 2011:550-5. 2011
    ..New information on the impact of DNMT inhibitors on the immune system and on stem cells will likely lead to novel uses of these drugs in MDS and other hematologic and nonhematologic malignancies...
  10. ncbi request reprint Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 11:8403-12. 2005
    ....
  11. ncbi request reprint Impact of prolonged infusions of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia
    Steven D Gore
    The Johns Hopkins Oncology Center, Department of Pediatrics, Johns Hopkins School of Medicine, Baltimore, Maryland 21231, USA
    Clin Cancer Res 8:963-70. 2002
    ..Two patients on the 21/28 schedule developed hematological improvement. Prolonged infusions of PB are well tolerated making this an attractive platform for the clinical investigation of HDAC inhibition...
  12. ncbi request reprint Durable molecular remissions with a single cycle of timed sequential consolidation chemotherapy in acute promyelocytic leukemia
    Steven D Gore
    The Sidney Kimmel Cancer Center at Johns Hopkins, Baltimore, Maryland 21231, USA
    Am J Hematol 79:119-27. 2005
    ..However, the toxicity of the consolidation module and the development of secondary myelodysplasia despite decreased total therapy emphasize the need to further improve and refine curative therapy for APL...
  13. pmc Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-azacytidine and entinostat in patients with myeloid malignancies
    Tamer E Fandy
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD, USA
    Blood 114:2764-73. 2009
    ..In conclusion, methylation reversal of candidate TSGs during cycle 1 of therapy was not predictive of clinical response to combination "epigenetic" therapy. This trial is registered with http://www.clinicaltrials.gov under NCT00101179...
  14. pmc DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Centre, Johns Hopkins Hospital, Baltimore, MD 21231, USA
    Semin Hematol 45:23-30. 2008
    ..Combination therapy offers the possibility of hematologic improvement and remission to myelodysplastic patients with previously untreatable disease...
  15. ncbi request reprint Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland 21231 1000, USA
    Clin Cancer Res 13:4467-73. 2007
    ..We have now completed a phase II study of sequential flavopiridol, ara-C, and mitoxantrone in 62 adults with poor-risk AML...
  16. pmc A phase 1 clinical-laboratory study of clofarabine followed by cyclophosphamide for adults with refractory acute leukemias
    Judith E Karp
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Blood 110:1762-9. 2007
    ..This clinical trial is registered with the National Cancer Institute's PDQ at www.clinicaltrials.gov as no. JHOC-J0561...
  17. pmc Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide
    Judith E Karp
    Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, MD 21231 1000, USA
    Blood 113:4841-52. 2009
    ..These clinical studies are registered at www.clinicaltrials.gov as #NCT00112853...
  18. pmc Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
    Judith E Karp
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231 1000, USA
    Leuk Res 34:877-82. 2010
    ..Short OS and DFS correlated with adverse cytogenetics, regardless of age or treatment in CR. The addition of allogeneic BMT in CR translates into long OS and DFS in the majority of eligible patients...
  19. pmc Differentiation therapy in poor risk myeloid malignancies: Results of a dose finding study of the combination bryostatin-1 and GM-CSF
    B Douglas Smith
    Johns Hopkins Medical Institute, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21287, USA
    Leuk Res 35:87-94. 2011
    ..We developed a dose finding trial to assess toxicity, differentiating activity, and clinical impact of the combination of bryostatin-1 and GM-CSF...
  20. pmc Extended follow-up of autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide (4-HC) purging for indolent or transformed non-Hodgkin lymphomas
    Yvette L Kasamon
    Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
    Biol Blood Marrow Transplant 17:365-73. 2011
    ..Thus, 4-HC-purged ABMT can produce extended remissions in a subgroup of patients with indolent lymphomas...
  21. pmc Arsenic trioxide - An old drug rediscovered
    Ashkan Emadi
    Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, United States
    Blood Rev 24:191-9. 2010
    ..The chemistry, mechanisms of action, and clinical side effects of As(2)O(3) are also discussed...
  22. pmc Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias
    Ivana Gojo
    University of Maryland Marlene and Stewart Greenebaum Cancer Center, Baltimore, MD 21201, USA
    Blood 109:2781-90. 2007
    ..No responses by classical criteria were seen. Our results show that MS-275 effectively inhibits HDAC in vivo in patients with advanced myeloid leukemias and should be further tested, preferably in patients with less-advanced disease...
  23. ncbi request reprint Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukaemia beyond first remission: a 10-year experience
    B Douglas Smith
    Johns Hopkins Oncology Center, Bunting Blaustein Cancer Research Building, Rm 246, 1650 Orleans Street, Baltimore, MD 21231, USA
    Br J Haematol 117:907-13. 2002
    ..4HC-purged autologous BMT produced results similar to allogeneic BMT for AML patients beyond first remission...
  24. pmc Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features
    Judith E Karp
    Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD 21231 1000, USA
    Clin Cancer Res 14:3077-82. 2008
    ..Tipifarnib is an oral farnesyltransferase inhibitor with activity in AML. We conducted a phase II trial of maintenance tipifarnib monotherapy for 48 adults with poor-risk AML in first CR...
  25. ncbi request reprint Six (or more) drugs in search of a mechanism: DNA methyltransferase and histone deacetylase inhibitors in the treatment of myelodysplastic syndromes
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, 1650 Orleans Street, Baltimore, MD 21231, USA
    J Natl Compr Canc Netw 4:83-90. 2006
    ..Such information will be critical in the development of more effective congeners and drug combinations in ongoing attempts to improve the outcome of patients with MDS...
  26. ncbi request reprint Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
    Michelle A Rudek
    Division of Medical Oncology, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    J Clin Oncol 23:3906-11. 2005
    ..To characterize the pharmacokinetic behavior of 5-azacitidine (5-AC), a cytidine nucleoside analog, when given with phenylbutyrate, a histone deaceytlase inhibitor...
  27. ncbi request reprint DNA demethylating agents and histone deacetylase inhibitors in hematologic malignancies
    Tamer E Fandy
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Cancer J 13:40-8. 2007
    ..This review focuses on the pharmacology of the known DNA methyltransferase and histone deacetylase inhibitors and their potential as promising anticancer drugs...
  28. ncbi request reprint Flavopiridol synergizes TRAIL cytotoxicity by downregulation of FLIPL
    Tamer E Fandy
    School of Pharmacy, Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD 21201, USA
    Cancer Chemother Pharmacol 60:313-9. 2007
    ..We investigated the effect of flavopiridol pretreatment on TRAIL cytotoxicity and on the expression of FLIP(L) in different TRAIL-resistant cell lines, because FLIP expression is known to confer TRAIL-resistance...
  29. ncbi request reprint Intravenous azacitidine for MDS
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
    Clin Adv Hematol Oncol 5:234. 2007
  30. ncbi request reprint Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies
    Steven D Gore
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Nat Clin Pract Oncol 2:S30-5. 2005
    ....
  31. ncbi request reprint Novel approaches for myelodysplastic syndromes: beyond hypomethylating agents
    Arturo Loaiza-Bonilla
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Hematol 17:104-9. 2010
    ..Several novel therapeutic approaches exist for treatment of patients with myelodysplastic syndrome, with goals to improve quality of life and prolong survival. This review highlights new therapies from the last 18 months...
  32. ncbi request reprint Oral valacyclovir as prophylaxis against herpes simplex virus reactivation during high dose chemotherapy for leukemia
    Robert Z Orlowski
    The Sidney Kimmel Comprehensive Cancer Center, Divisions of Hematological Malignancies, Baltimore, Maryland 21287 8985, USA
    Leuk Lymphoma 45:2215-9. 2004
    ....
  33. ncbi request reprint Acute myeloid leukemia is characterized by Wnt pathway inhibitor promoter hypermethylation
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD 21231, USA
    Leuk Lymphoma 51:1711-9. 2010
    ....
  34. pmc Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies
    Ying Ye
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205, USA
    Cancer Res 69:8482-90. 2009
    ....
  35. ncbi request reprint DNA methyltransferase inhibitors: class effect or unique agents?
    Elizabeth A Griffiths
    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, USA
    Leuk Lymphoma 49:650-1. 2008
  36. ncbi request reprint Emerging drugs for the treatment of myelodysplastic syndrome
    Philip J Nivatpumin
    Division of Hematologic Malignancies, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA
    Expert Opin Emerg Drugs 10:569-90. 2005
    ..Our improved understanding of the molecular pathogenesis of MDS has resulted in several new promising therapeutic agents. This review will consider the rational development of new agents based on the molecular biology of MDS...
  37. ncbi request reprint Decitabine
    Steven D Gore
    Nat Rev Drug Discov 5:891-2. 2006
  38. ncbi request reprint Commentary: topoisomerases as targets in acute leukemia: I, II, I plus II or none?
    Sami N Malek
    Leuk Res 27:1-3. 2003
  39. ncbi request reprint Addition of histone deacetylase inhibitors in combination therapy
    Hetty E Carraway
    J Clin Oncol 25:1955-6. 2007
  40. ncbi request reprint State of the translational science: summary of Baltimore workshop on gene re-expression as a therapeutic target in cancer January 2003
    Arthur Zelent
    Section of Hematological Oncology, Institute of Cancer Research, Chester Beatty Laboratories, London, England
    Clin Cancer Res 10:4622-9. 2004
    ..Other classes of agents that may be rationally combined with these classes of drugs include retinoids, steroid hormones, and cytotoxic drugs...
  41. pmc Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics
    Arthur Zelent
    Institute of Cancer Research, Sutton, Surrey, United Kingdom
    Cancer Res 68:4967-70. 2008
  42. ncbi request reprint Clinical translation of epigenetics in cancer: eN-CORe--a report on the second workshop
    Arthur Zelent
    Section of Hemato Oncology, Institute of Cancer Research, London, United Kingdom
    Mol Cancer Ther 4:1810-9. 2005
    ..The aim of this article is to summarize topics discussed at this workshop and highlight conclusions as to the immediate and long-term future of epigenetic therapy in cancer...
  43. pmc Alkyl-substituted polyaminohydroxamic acids: a novel class of targeted histone deacetylase inhibitors
    Sheeba Varghese
    Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan 48202, USA
    J Med Chem 48:6350-65. 2005
    ..On the basis of these results, PAHAs 6-21 represent an important new chemical class of HDAC inhibitors...
  44. ncbi request reprint Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
    Bruce D Cheson
    Department of Hematology Oncology, Georgetown University Hospital, Washington, DC, USA
    Blood 108:419-25. 2006
    ..Because limitations of the IWG criteria have surfaced, based on practical and reported experience, some modifications were warranted. In this report, we present recommendations for revisions of some of the initial criteria...
  45. ncbi request reprint Central role of Fas-associated death domain protein in apoptosis induction by the mitogen-activated protein kinase kinase inhibitor CI-1040 (PD184352) in acute lymphocytic leukemia cells in vitro
    Xue Wei Meng
    Division of Oncology Research, Guggenheim 1342C, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA
    J Biol Chem 278:47326-39. 2003
    ..Collectively, these results identify the MAPK pathway as a potential therapeutic target in ALL and delineate a mechanism by which MEK inhibition triggers apoptosis in ALL cells...
  46. ncbi request reprint Autoimmune phenomena in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia
    Muhammad Wasif Saif
    Division of Hematology Oncology, Wallace Tumour Institute, University of Alabama, Room 262 A, 1824 6th Avenue South, Birmingham, AL 35294 3300, USA
    Leuk Lymphoma 43:2083-92. 2002
    ..We also review the incidence, nature, course and response to therapy of these manifestations and discuss potential pathogenic mechanisms...
  47. ncbi request reprint Myelodysplastic syndromes clinical practice guidelines in oncology
    Peter L Greenberg
    Stanford Hospital and Clinics, Stanford, CA, USA
    J Natl Compr Canc Netw 4:58-77. 2006
  48. ncbi request reprint Future directions for the use of hypomethylating agents
    Guillermo Garcia-Manero
    Department of Leukemia, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 42:S50-9. 2005
    ..This review discusses the potential use of methylation reversing agents in the treatment of solid tumors and in benign hematologic disorders along with the rationale for combination therapies using hypomethylating agents...

Research Grants11

  1. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2007
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. ..
  2. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2000
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  3. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2006
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. ..
  4. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2005
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. ..
  5. Arsenic Trioxide in Primary Curative APL Therapy
    Steven Gore; Fiscal Year: 2004
    ..Success of this trial will potentially be followed by the testing of regimen against more conventional and more extensive treatment for APL in a Phase III trial. ..
  6. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2002
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  7. DNA METHYLTRANSFERASE/HISTONE DEACETYLASE INHIBITION
    Steven Gore; Fiscal Year: 2001
    ..This will enable determination of the "molecular response rate" to this therapy and preliminary exploration of correlation between these molecular endpoints and clinical response. ..
  8. Mechanism of combined 'epigenetic therapy' in myeloid malignancies
    Steven Gore; Fiscal Year: 2009
    ....